Limits...
Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer.

Matias BF, de Oliveira TM, Rodrigues CM, Abdalla DR, Montes L, Murta EF, Michelin MA - Clin Med Insights Oncol (2013)

Bottom Line: The CD14+ TNF-α+ population was significantly increased (P < 0.04) when patients received the vaccine; IL-2 expression in both NK cells and in B lymphocytes was increased after a transient initial increase showed a nearly significant decrease (P < 0.07 and P < 0.06 respectively), whereas the CD19+ and CD56+ populations did not show significant changes.Dendritic cell-based immunotherapy led to increased secretion of IFN-γ and IL-12 and reduced secretion of TGF-β.In conclusion, it is likely that the autologous dendritic cell vaccine stimulated the immune cells from the peripheral blood of patients with cancer and generally increased the production of Th1 cytokines, which are related to immunomodulatory responses against cancer.

View Article: PubMed Central - PubMed

Affiliation: Oncology Research Institute (IPON), Federal University of the Triângulo Mineiro (UFTM), Brazil.

ABSTRACT
The objective of this study was to evaluate some of the mechanisms involved in the activation of the immune system in patients with advanced-stage cancer (n = 7) who received an autologous dendritic cell vaccine. We examined the immune response mediated by macrophages (CD14+), natural killer cells (CD56+), and B lymphocytes (CD19+) by flow cytometry and assessed the expression of Th1 (IFN-γ, TNF-α, IL-2, and IL-12), Th2 (IL-4), and Treg (TGF-β) cytokines by flow cytometry and an enzyme-linked immunosorbent assay. The CD14+ TNF-α+ population was significantly increased (P < 0.04) when patients received the vaccine; IL-2 expression in both NK cells and in B lymphocytes was increased after a transient initial increase showed a nearly significant decrease (P < 0.07 and P < 0.06 respectively), whereas the CD19+ and CD56+ populations did not show significant changes. Dendritic cell-based immunotherapy led to increased secretion of IFN-γ and IL-12 and reduced secretion of TGF-β. In conclusion, it is likely that the autologous dendritic cell vaccine stimulated the immune cells from the peripheral blood of patients with cancer and generally increased the production of Th1 cytokines, which are related to immunomodulatory responses against cancer.

No MeSH data available.


Related in: MedlinePlus

Linear trends for the percentage of fluorescence for samples showing significant expression of CD14, CD19, and CD56 with IL-2 and TNF-α in patients receiving treatment with the DC vaccine.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3733716&req=5

f1-cmo-7-2013-165: Linear trends for the percentage of fluorescence for samples showing significant expression of CD14, CD19, and CD56 with IL-2 and TNF-α in patients receiving treatment with the DC vaccine.

Mentions: Figure 1 shows the tendencies of the markers to show significant or near-significant changes when we analyzed the influence of the DC vaccine in treating patients with advanced cancer. Before and during DC-based immunotherapy, we collected blood samples to measure serum cytokine levels. Th1 cytokines were capacitated by DC-based immunotherapy (Table 2). Over the course of therapy, the IFN-γ cytokine showed an arguable increase in synthesis (Fig. 2). IL-12 showed a substantial, but not significant, increase in production after therapy with DCs and over the course of treatment (Fig. 2). The serum expressions of IL-4 and TGF-β generally decreased after the start of treatment (Table 3 and Figure 2).


Influence of immunotherapy with autologous dendritic cells on innate and adaptive immune response in cancer.

Matias BF, de Oliveira TM, Rodrigues CM, Abdalla DR, Montes L, Murta EF, Michelin MA - Clin Med Insights Oncol (2013)

Linear trends for the percentage of fluorescence for samples showing significant expression of CD14, CD19, and CD56 with IL-2 and TNF-α in patients receiving treatment with the DC vaccine.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3733716&req=5

f1-cmo-7-2013-165: Linear trends for the percentage of fluorescence for samples showing significant expression of CD14, CD19, and CD56 with IL-2 and TNF-α in patients receiving treatment with the DC vaccine.
Mentions: Figure 1 shows the tendencies of the markers to show significant or near-significant changes when we analyzed the influence of the DC vaccine in treating patients with advanced cancer. Before and during DC-based immunotherapy, we collected blood samples to measure serum cytokine levels. Th1 cytokines were capacitated by DC-based immunotherapy (Table 2). Over the course of therapy, the IFN-γ cytokine showed an arguable increase in synthesis (Fig. 2). IL-12 showed a substantial, but not significant, increase in production after therapy with DCs and over the course of treatment (Fig. 2). The serum expressions of IL-4 and TGF-β generally decreased after the start of treatment (Table 3 and Figure 2).

Bottom Line: The CD14+ TNF-α+ population was significantly increased (P < 0.04) when patients received the vaccine; IL-2 expression in both NK cells and in B lymphocytes was increased after a transient initial increase showed a nearly significant decrease (P < 0.07 and P < 0.06 respectively), whereas the CD19+ and CD56+ populations did not show significant changes.Dendritic cell-based immunotherapy led to increased secretion of IFN-γ and IL-12 and reduced secretion of TGF-β.In conclusion, it is likely that the autologous dendritic cell vaccine stimulated the immune cells from the peripheral blood of patients with cancer and generally increased the production of Th1 cytokines, which are related to immunomodulatory responses against cancer.

View Article: PubMed Central - PubMed

Affiliation: Oncology Research Institute (IPON), Federal University of the Triângulo Mineiro (UFTM), Brazil.

ABSTRACT
The objective of this study was to evaluate some of the mechanisms involved in the activation of the immune system in patients with advanced-stage cancer (n = 7) who received an autologous dendritic cell vaccine. We examined the immune response mediated by macrophages (CD14+), natural killer cells (CD56+), and B lymphocytes (CD19+) by flow cytometry and assessed the expression of Th1 (IFN-γ, TNF-α, IL-2, and IL-12), Th2 (IL-4), and Treg (TGF-β) cytokines by flow cytometry and an enzyme-linked immunosorbent assay. The CD14+ TNF-α+ population was significantly increased (P < 0.04) when patients received the vaccine; IL-2 expression in both NK cells and in B lymphocytes was increased after a transient initial increase showed a nearly significant decrease (P < 0.07 and P < 0.06 respectively), whereas the CD19+ and CD56+ populations did not show significant changes. Dendritic cell-based immunotherapy led to increased secretion of IFN-γ and IL-12 and reduced secretion of TGF-β. In conclusion, it is likely that the autologous dendritic cell vaccine stimulated the immune cells from the peripheral blood of patients with cancer and generally increased the production of Th1 cytokines, which are related to immunomodulatory responses against cancer.

No MeSH data available.


Related in: MedlinePlus